<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">PYRAZINAMIDE</span><br/>(peer-a-zin'a-mide)<br/><span class="topboxtradename">PZA, </span><span class="topboxtradename">Tebrazid <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">antiinfective</span>; <span class="classification">antituberculosis agent</span><br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg tablets</p>
<h1><a name="action">Actions</a></h1>
<p>Pyrazinoic acid amide, analog of nicotinamide which is bacteriostatic against <i>Mycobacterium tuberculosis.</i> When employed alone, resistance may develop in 67 wk; therefore, administration with other effective agents is recommended.
         Appears to interfere with renal capacity to concentrate and excrete uric acid. Thus it may cause hyperuricemia.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Bacteriostatic against <i>Mycobacterium tuberculosis</i>. Not used as sole agent against TB infection.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term therapy of advanced tuberculosis before surgery and to treat patients unresponsive to primary agents (e.g., isoniazid,
         streptomycin).
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Severe liver damage, pregnancy (category C), and lactation.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Presence or family history of gout or diabetes mellitus; impaired kidney function; history of peptic ulcer; acute intermittent
         porphyria.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Tuberculosis</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> 1535 mg/kg/d in 34 divided doses (max: 2 g/d)<br/><span class="rdage">Child:</span> <span class="rdroute">PO</span> 2040 mg/kg/d divided q1224h (max: 2 g/d)<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Discontinue drug if hepatic reactions (jaundice, pruritus, icteric sclerae, yellow skin) or hyperuricemia with acute gout
            (severe pain in great toe and other joints) occur.
         </li>
<li>Store at 15°30° C (59°86° F) in tightly closed container.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">Body as a Whole:</span> <span class="speceff-common">Active gout,</span> arthralgia, lymphadenopathy. <span class="typehead">Urogenital:</span> Difficulty in urination. <span class="typehead">CNS:</span> Headache. <span class="typehead">Skin:</span>  Urticaria. <span class="typehead"> Hematologic:</span> Hemolytic anemia, decreased plasma prothrombin. <span class="typehead">GI:</span> Splenomegaly, <span class="speceff-life">fatal hemoptysis</span>, aggravation of peptic ulcer, <span class="speceff-common">hepatotoxicity, abnormal liver function tests.</span> <span class="typehead">Metabolic:</span> <span class="speceff-common">Rise in serum uric acid.</span>
<h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>Pyrazinamide may produce a temporary decrease in <span class="alt">17-ketosteroids</span> and an increase in <span class="alt">protein-bound iodine.</span>
</p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Increase in liver toxicity (including fatal hepatoxicity in when treating latent TB) with <b>rifampin.</b>
<h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from GI tract. <span class="typehead">Peak:</span> 2 h. <span class="typehead">Distribution:</span> Crosses bloodbrain barrier. <span class="typehead">Metabolism:</span> Metabolized in liver. <span class="typehead">Elimination:</span> Excreted slowly in urine. <span class="typehead">Half-Life:</span> 910 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effect</span></p>
<ul>
<li>Observe and supervise closely. Patients should receive at least one other effective antituberculosis agent concurrently.</li>
<li>Examine patients at regular intervals and question about possible signs of toxicity: Liver enlargement or tenderness, jaundice,
            fever, anorexia, malaise, impaired vascular integrity (ecchymoses, petechiae, abnormal bleeding).
         </li>
<li>Hepatic reactions appear to occur more frequently in patients receiving high doses.</li>
<li>Lab tests: Obtain liver function tests (especially AST, ALT, serum bilirubin) prior to and at 24 wk intervals during
            therapy. Blood uric acid determinations are advised before, during, and following therapy.
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report to physician onset of difficulty in voiding. Keep fluid intake at 2000 mL/d if possible.</li>
<li>Monitor blood glucose (diabetics) for possible loss of glycemic control.</li>
<li>Do not breast feed while taking this drug without consulting physician.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>